First-in-class small molecule inhibitor shows promise against pancreatic cancer in preclinical studies

Mayo Clinic researchers person developed an experimental cause with the assistance of artificial quality (AI) to people the "undruggable" PDZ domain of the GIPC1 protein, which helps antithetic types of cancer, including pancreatic cancer, turn and defy treatment. In laboratory studies, the cause slowed tumor growth, improved endurance and enhanced the effects of the chemotherapy cause gemcitabine.